UNLIMITED TURBO BEAR - NOVO-NORDISK B | Real-time Euronext Paris 04:39:07 2024-05-29 EDT | ||
| 0.735 EUR | +9.70% |
|
| Current month | -20.71% | ||
| 1 month | -25.14% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-05-29 | 0.735 | +9.70% |
| 24-05-28 | 0.67 | +3.08% |
| 24-05-27 | 0.65 | +12.07% |
| 24-05-24 | 0.58 | +13.73% |
| 24-05-23 | 0.51 | -21.54% |
Real-time Euronext Paris
Last update May 29, 2024 at 04:39 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| L272S | |
| ISIN | DE000SU2UT22 |
| Date issued | 2023-11-28 |
| Strike | 1,018 kr |
| Maturity | Unlimited |
| Parity | 20 : 1 |
| Emission price | 2.11 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.535 € |
|---|---|
| Lowest since issue | 0.505 € |
| Spread | 0.01 € |
| Spread % | 1.35% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
915.7
DKK
Average target price
909.2
DKK
Spread / Average Target
-0.71%
- Stock Market
- Certificates
- L272S Certificat
